Flumazenil Transdermal Patch for Addiction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The short half-life and low oral bioavailability of flumazenil limit its use to clinical settings, making intravenous infusion challenging, especially for patients with compromised venous access, and there is a need for less invasive treatment methods for drug withdrawal and addiction.
Innovation Solution
A pharmaceutical preparation of flumazenil at a concentration of 0.11 to 0.7 mg/ml in saline at pH 6.5 to 7.0 for subcutaneous administration at a continuous rate of 40 µg/h to 1000 µg/h over several days, allowing patient-controlled delivery via pumps, nasal sprays, or patches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If intravenous infusion of flumazenil is used, then rapid onset of action is achieved, but patient compliance deteriorates and clinical setting dependency increases
Solution Approach 1:
The patent replaces the intravenous mechanical injection system with a transdermal delivery system using patches or iontophoresis devices, eliminating the need for venous access while maintaining effective drug delivery to achieve rapid therapeutic effects with improved patient compliance
Solution Approach 2:
The patent introduces transdermal patches or iontophoresis devices as intermediary delivery systems that mediate between the flumazenil drug and the patient's body, enabling non-invasive administration while achieving rapid onset through controlled transdermal absorption
2Reliability
If intravenous infusion is used, then effective treatment is achieved, but device complexity and invasiveness increase
Solution Approach 1:
The patent extracts the drug delivery function from the complex intravenous infusion system and implements it through simple transdermal patches or portable iontophoresis devices, maintaining treatment effectiveness while eliminating the complexity of IV access and infusion equipment
Solution Approach 2:
The patent employs disposable transdermal patches that can be applied and removed without medical intervention, replacing the need for reusable IV equipment and reducing overall system complexity while ensuring reliable drug delivery
3Reliability
If flumazenil is administered, then benzodiazepine overdose is reversed, but withdrawal symptoms and seizures may occur in physically dependent patients
Solution Approach 1:
The patent implements periodic or pulsed drug delivery through transdermal patches that release flumazenil in controlled intervals, preventing the sudden receptor blockade that causes withdrawal symptoms while maintaining sufficient antagonism to reverse overdose effects
Solution Approach 2:
The patent uses lower doses of flumazenil delivered continuously through transdermal systems, providing partial antagonism that reverses overdose effects without completely blocking all benzodiazepine receptor activity, thereby avoiding severe withdrawal symptoms in dependent patients
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to unique delivery systems and the use of an imidazobenzodiazepine derivative, such as flumazenil either alone or in combination with other receptor antagonists in the treatment of disease or medical disorders.